Adam Pavlicek, PhD


Dr. Pavlicek received his PhD from the Jacques Monod Institute and has over 10 years of experience in the pharmaceutical industry at companies such as Pfizer and Regulus Therapeutics. He contributed to biomarker and patient selection strategies for several late stage projects at Pfizer including palbociclib (IBRANCEĀ®) and crizotinib(Xalcori). Most recently, he served as Senior Director of Discovery Technologies and Orphan Diseases at Regulus, where he established and oversaw the CNS and ocular therapeutic areas.